Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Pre-screening stage:

• People who have been diagnosed (confirmed by laboratory testing of tissue) with advanced or metastatic bowel or rectal cancer that has spread and cannot be surgically removed
• People who are currently receiving or have previously received treatment for their metastatic colorectal cancer
• People whose cancer cannot be removed by surgery, but who are able to have a needle biopsy taken from at least one area where the cancer has spread
• People who are generally well enough to carry out normal daily activities, with only minor limitations (confirm with trial site what this means for individual circumstances)
• People whose cancer can be measured or assessed on scans according to standard criteria
• People who are able to give their own informed consent to participate

Main study stage:

• People who have been diagnosed (confirmed by laboratory testing of tissue) with advanced or metastatic bowel or rectal cancer
• People who have already completed at least two rounds of standard chemotherapy for their metastatic colorectal cancer (the trial site can explain how certain earlier treatment histories are counted)
• People whose tumour has been fully analysed — including its genetic makeup and how its cells respond to drugs in laboratory testing — and whose medical team has recommended one of the specific targeted treatments available in this trial
• People whose cancer can be measured or assessed on scans
• People who are generally well enough to carry out normal daily activities, with only minor limitations
• People who are able to swallow tablets or capsules without difficulty, and who do not have a condition that prevents the body from absorbing oral medication (for treatments taken by mouth)
• People who are willing to use appropriate contraception throughout the trial and for up to seven months after treatment ends; male participants, including those who have had a vasectomy, must agree to use effective barrier contraception or complete abstinence for the duration of treatment and for six months after the last dose
• People whose blood test results show that their bone marrow, liver, and kidneys are functioning at an acceptable level as defined by the trial

Who may not be able to join:

Pre-screening stage:

• People with other significant health conditions that, in their treating doctor's opinion, would make participation unsafe or difficult

Main study stage:

• People who still have significant side effects (above a moderate level, except for nerve-related tingling/numbness or hair loss) from cancer treatment received within the four weeks before registering; people with severe nerve-related side effects are also excluded
• People who have previously been treated with the specific study drug being considered for them
• People whose tumour has a known genetic change that makes it resistant to a particular drug available in this trial (they may still be considered for other drugs in the trial if they meet all other criteria)
• People who are currently receiving other cancer treatments, including chemotherapy, biological therapies, radiation, or hormonal therapies (other than hormone replacement); certain blood-thinning medications may be permitted unless restricted by the specific drug's guidelines
• People who are pregnant, breastfeeding, or unwilling to use the required contraception methods
• People who have cancer that has spread to the brain or central nervous system
• People with serious pre-existing heart conditions, including uncontrolled chest pain, irregular heart rhythms, or heart failure with symptoms
• People whose heart pumping function is known to be significantly reduced (below 40%)
• People who have had a stroke, mini-stroke, or heart attack within the six months before starting the study treatment
• People who have had a serious episode of gastrointestinal bleeding within one month before starting treatment
• People with other significant health conditions that, in their treating doctor's opinion, would make participation unsafe or difficult
• People who meet any contraindication or exclusion criteria specific to the individual drug assigned to them in the trial

Important: Always verify eligibility with the trial site directly before applying.